BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 35092504)

  • 21. Identifying
    Xiang X; Gao LM; Zhang Y; Zhu Q; Zhao S; Liu W; Ye Y; Tang Y; Zhang W
    PeerJ; 2023; 11():e16618. PubMed ID: 38099311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
    Peng W; Wu J; Feng J
    Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis.
    Punnoose E; Peale FV; Szafer-Glusman E; Lei G; Bourgon R; Do AD; Kim E; Zhang L; Farinha P; Gascoyne RD; Munoz FJ; Martelli M; Mottok A; Salles GA; Sehn LH; Seymour JF; Trnĕný M; Oestergaard MZ; Mundt KE; Vitolo U
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):267-278.e10. PubMed ID: 33303421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
    Wong KK; Gascoyne DM; Brown PJ; Soilleux EJ; Snell C; Chen H; Lyne L; Lawrie CH; Gascoyne RD; Pedersen LM; Møller MB; Pulford K; Murphy D; Green TM; Banham AH
    Leukemia; 2014 Feb; 28(2):362-72. PubMed ID: 23884370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma.
    Fang Y; Zhang MC; He Y; Li C; Fang H; Xu PP; Cheng S; Zhao Y; Feng Y; Liu Q; Wang L; Zhao WL
    Signal Transduct Target Ther; 2023 Oct; 8(1):381. PubMed ID: 37798292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening of key genes associated with R‑CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B‑cell lymphoma.
    Liu R; Chen Z; Wang S; Zhao G; Gu Y; Han Q; Chen B
    Mol Med Rep; 2019 Oct; 20(4):3679-3690. PubMed ID: 31485671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction significance of autophagy-related genes in survival probability and drug resistance in diffuse large B-cell lymphoma.
    Xiong D; Wei X; Huang W; Zheng J; Feng R
    Aging (Albany NY); 2024 Jan; 16(2):1049-1076. PubMed ID: 38240686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. c-FLIP does not correlate with response to immunochemotherapy treatment and outcome of patients with nodal diffuse large B-cell lymphoma.
    Markovic O; Marisavljevic D; Cemerikic-Martinovic V; Filipovic B; Radovanović S; Zdravković M; Stanisavljevic D; Mihaljevic B
    Biomed Pharmacother; 2013 Jun; 67(5):445-9. PubMed ID: 23582793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma.
    Zhang C; Lin Q; Li C; Qiu Y; Chen J; Zhu X
    Front Immunol; 2023; 14():1277695. PubMed ID: 38155967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database.
    Luo B; Gu YY; Wang XD; Chen G; Peng ZG
    Pathol Res Pract; 2018 Nov; 214(11):1854-1867. PubMed ID: 30244948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.
    Liu Y; Guo X; Zhan L; Wang L; Wang X; Jiang M
    Comput Math Methods Med; 2021; 2021():4468140. PubMed ID: 34422089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prognostic immune risk score for diffuse large B-cell lymphoma.
    Ma SY; Tian XP; Cai J; Su N; Fang Y; Zhang YC; Wang JN; Peter Gale R; Cai QQ
    Br J Haematol; 2021 Jul; 194(1):111-119. PubMed ID: 33942291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene set-based identification of two immune subtypes of diffuse large B cell lymphoma for guiding immune checkpoint blocking therapy.
    Li Z; Duan Y; Ke Q; Wang M; Cen H; Zhu X
    Front Genet; 2022; 13():1000460. PubMed ID: 36276947
    [No Abstract]   [Full Text] [Related]  

  • 34. IQGAP2 acts as an independent prognostic factor and is related to immunosuppression in DLBCL.
    Tang T; Wang J; Zhang L; Cheng Y; Saleh L; Gu Y; Zhang H
    BMC Cancer; 2021 May; 21(1):603. PubMed ID: 34034707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.
    Falduto A; Cimino F; Speciale A; Musolino C; Gangemi S; Saija A; Allegra A
    Blood Rev; 2017 Jul; 31(4):235-249. PubMed ID: 28262268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Porrata LF; Rsitow K; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Habermann TM; Witzig TE; Colgan JP; Nowakowski GS; Thompson CA; Markovic SN
    Leukemia; 2010 Jul; 24(7):1343-9. PubMed ID: 20485372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers.
    El Hussein S; Shaw KRM; Vega F
    Mod Pathol; 2020 Dec; 33(12):2422-2436. PubMed ID: 32620919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
    Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS
    Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B-cell lymphoma.
    Dong H; Wang Q; Zhang G; Li N; Yang M; An Y; Xie L; Li H; Zhang L; Zhu W; Zhao S; Zhang H; Guo X
    Cancer Med; 2020 Mar; 9(5):1790-1797. PubMed ID: 31918459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrated bioinformatics analysis reveals dynamic candidate genes and signaling pathways involved in the progression and prognosis of diffuse large B-cell lymphoma.
    Charwudzi A; Meng Y; Hu L; Ding C; Pu L; Li Q; Xu M; Zhai Z; Xiong S
    PeerJ; 2021; 9():e12394. PubMed ID: 34760386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.